- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06576674
Satiety and Alcohol Challenge (SatTAC)
November 20, 2025 updated by: University of North Carolina, Chapel Hill
Effect of a Dietary Supplement on Satiety and Acute Responses to Laboratory Alcohol Challenge
The goal of this pilot study is to identify the role of satiety on responses to alcohol drinking using human subject laboratory methods.
Satiety will be manipulated over two sessions using a dietary supplement (fiber+green tea) or a calorically matched placebo.
Responses to an acute alcohol challenge are measured.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Participants will receive a beverage containing either a dietary supplement (10g Fibersol®-2 mixed with water and aspartame sweetener for taste + 725mg decaffeinated green tea extract capsule) or a calorically matched placebo supplement (Aspartame sweetener mixed with water + aspartame capsule) counterbalanced at two separate visits.
Forty-five minutes after the dietary supplement, a priming drink (calculated to achieve 0.03g/dL Blood Alcohol Concentration; BAC) is administered.
Response to alcohol is measured using standardized questionnaires and a cognitive task.
Then over a 2-hour period, additional mini-drinks are administered.
Responses to standardized questionnaires are collected after each drink.
Study Type
Interventional
Enrollment (Actual)
64
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Age 21-45
- Meeting NIAAA criteria for current at-risk drinking (i.e., >7/14 drinks in one week for women/men, with at least one episodes of 4+/5+ drinks in the past 30 days)
- Willingness to complete laboratory sessions involving blood draws and alcohol administration
- Ability to communicate and read in English
- Body mass index (BMI) of 21 - 30 kg/m^2
Exclusion Criteria:
- Meets past-year criteria for severe Alcohol Use Disorder (>7 of 11 symptoms endorsed) or AUDIT score of 20+
- Meeting past-year criteria for a substance use disorder (with the exception of alcohol, tobacco or mild cannabis use disorder)
- Current engagement in alcohol treatments, or currently engaged in intentional efforts to quit alcohol use
- Current use of weight control medications
- Lifetime diagnosis of severe mental illness (including schizophrenia and bipolar disorder)
- History of suicide attempt, or psychiatric hospitalization in the last 6 months
- History of diabetes
- Medical conditions or medications for which alcohol is contraindicated
- Pregnant, nursing, or trying to become pregnant
- Plans to travel during the duration of study participation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: dietary supplement, then placebo
Participants receive a dietary supplement at the first study session (10g Fibersol®-2 mixed with water and aspartame sweetener + 725mg decaffeinated green tea extract capsule), and then the next study session they receive the placebo supplement (Aspartame sweetener mixed with water + aspartame capsule).
Participants will also receive a drink containing alcohol (vodka + cranberry mixer) on both sessions.
|
10g fiber + 750mg green tea supplement will be administered at experimental arm
Other Names:
Aspartame sweetener mixed with water + aspartame capsule
Other Names:
alcohol administered up to a target BAC 0.06g/dL during lab sessions
Other Names:
|
|
Experimental: placebo, then dietary supplement
Participants receive a placebo supplement at the first study session (Aspartame sweetener mixed with water + aspartame capsule), then the next session they receive the dietary supplement (10g Fibersol®-2 mixed with water and aspartame sweetener + 725mg decaffeinated green tea extract capsule).
Participants will also receive a drink containing alcohol (vodka + cranberry mixer) on both sessions.
|
10g fiber + 750mg green tea supplement will be administered at experimental arm
Other Names:
Aspartame sweetener mixed with water + aspartame capsule
Other Names:
alcohol administered up to a target BAC 0.06g/dL during lab sessions
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Alcohol Specific Satiety Score
Time Frame: baseline to 60 minutes
|
The Alcohol-specific Satiety Questionnaire is a 16-item instrument designed to measure satiety to alcohol's effects.
Ratings are made from Not at all; 0 to Extremely; 10, yielding total scores from 0 to 160 with higher values representing greater alcohol-specific satiety.
|
baseline to 60 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Positive Affect Based on Subjective Effects of Alcohol Scale Score
Time Frame: baseline to 60 minutes
|
The Subjective Effects of Alcohol Scale (SEAS) (0-70, 10 point scale) is a 14 item instrument designed to measure the magnitude of alcohol's subjective effects.
Ratings are made from Not at all; 0 to Extremely; 10, yielding total scores from 0 to 70 with higher values indicating a greater subjective response to alcohol.
|
baseline to 60 minutes
|
|
Change in Subjective Stimulation (Biphasic Alcohol Effects Scale)
Time Frame: baseline to 60 minutes
|
The Biphasic Alcohol Effect Scale (BAES) is a 14-item instrument designed to measure the stimulant and sedative subjective effects of alcohol.
Ratings are made from Not at all; 0 to Extremely; 10, yielding total scores from 0 to 70 with higher values indicating a greater subjective response to alcohol.
|
baseline to 60 minutes
|
|
Change in Attention Bias to Alcohol Score
Time Frame: 30 minutes after alcohol administration
|
The Visual Dot-Probe Paradigm is used to measure attention bias to alcohol.
Participants are asked to detect a target stimulus that is embedded in a matrix of distracting stimuli (e.g., a target stimulus, an alcohol related image, might be embedded in a matrix of neutral images).
Attention biases are inferred from faster response times to detect a alcohol related stimulus in a matrix of neutral stimuli relative to response time to detect neutral stimuli in neutral matrices.
Thus, positive times reflect attention bias toward alcohol, whereas negative times reflect attention bias away from alcohol.
|
30 minutes after alcohol administration
|
|
Change in Alcohol Demand Score
Time Frame: baseline to 60 minutes
|
The Alcohol Purchase Task is a 20-question self-report measure which asks participants about the number of drinks they would purchase and consume based at different monetary costs.
Intensity scores reflect the number of drinks that would be purchased when cost is zero.
|
baseline to 60 minutes
|
|
Change in Alcohol Urge Questionnaire Score
Time Frame: baseline to 60 minutes
|
The Alcohol Urge Questionnaire (AUQ) is an 8 item instrument designed to measure the magnitude of alcohol's subjective effects.
Ratings are made from Strongly agree; 1 to Agree; 7, yielding average scores from 1 to 7 with higher values indicating a greater alcohol craving.
|
baseline to 60 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Jimikaye Courtney, PhD, University of North Carolina, Chapel Hill
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 3, 2024
Primary Completion (Actual)
April 9, 2025
Study Completion (Actual)
April 9, 2025
Study Registration Dates
First Submitted
August 26, 2024
First Submitted That Met QC Criteria
August 26, 2024
First Posted (Actual)
August 29, 2024
Study Record Updates
Last Update Posted (Actual)
December 5, 2025
Last Update Submitted That Met QC Criteria
November 20, 2025
Last Verified
August 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 24-1095
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Deidentified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.
IPD Sharing Time Frame
beginning 9 and continuing for 36 months following publication
IPD Sharing Access Criteria
Investigator has approved IRB, IEC, or REB and an executed data use/sharing agreement with UNC.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcohol Drinking
-
University of North Carolina, Chapel HillNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedDrinking Behavior | Adolescent Behavior | Drinking, Alcohol | Alcohol Drinking, AdolescentUnited States
-
University of Auckland, New ZealandTe Hiringa Hauora/Health Promotion AgencyCompletedDrinking, Alcohol | Consumption, AlcoholNew Zealand
-
Penn State UniversityNot yet recruiting
-
Boston University Charles River CampusActive, not recruiting
-
The Hong Kong Polytechnic UniversityNot yet recruitingHazardous Drinking | Harmful Alcohol Use
-
University of WyomingRecruiting
-
Binghamton UniversityNot yet recruitingUnderage Drinking | Drinking, Teen | Adolescent Alcohol UseUnited States
-
Butler HospitalNational Institute of General Medical Sciences (NIGMS)CompletedDrinking, AlcoholUnited States
-
The University of Hong KongRecruitingmHealth Intervention | AlcoholHong Kong
-
Real Prevention, LLCCompletedUnderage Drinking | Alcohol Use, UnderageUnited States
Clinical Trials on Dietary Fiber + Green Tea Extract
-
University of MinnesotaNational Cancer Institute (NCI)Completed
-
Taipei City HospitalNational Yang Ming UniversityCompletedType 2 Diabetes | HyperlipidemiaTaiwan
-
Richard WhelanSt. Luke's-Roosevelt Hospital CenterTerminatedColon CancerUnited States
-
The University of Hong KongCompleted
-
Martin-Luther-Universität Halle-WittenbergUniversity of Ulm; Deutsche Krebshilfe e.V., Bonn (Germany); KKS NetzwerkCompletedColorectal Serrated Adenomas | Colorectal Tubular Adenomas | Colorectal Villous Adenomas | Colorectal Tubulovillous AdenomasGermany
-
Erzurum Technical UniversityCompletedExercise Physiology | Nutritional SupplementationTurkey (Türkiye)
-
National Eye Institute (NEI)Completed
-
MRC Human Nutrition ResearchCompletedDietary Supplements | Diet, Food, and NutritionUnited Kingdom
-
Charite University, Berlin, GermanyCompleted
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedProstate CancerUnited States